WebApr 19, 2024 · Adaptimmune anticipates filing a biologics licence application for its MAGE-A4-targeting TCR-T cell therapy afamitresgene autoleucel for use in synovial sarcoma later this year. Immatics also has...
Did you know?
WebThe tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T-cells into CD8+ cytotoxic T-cells. WebApr 19, 2024 · MAGE-A4/8. Various solid tumours. Phase Ia. IMA202. Immatics. MAGE-A1. Various solid tumours. Phase Ia. FH-TCR-T msln. Fred Hutchinson Cancer Center. …
WebOct 20, 2024 · Following apheresis, T-cells are isolated, transduced with a lentiviral vector containing the MAGE-A4 c1032 TCR, and expanded. Prior to transduced cell infusion, patients are given lymphodepleting chemotherapy (Flu 30 mg/m 2 /d and Cy 600 mg/m 2 /d, on days -7, -6 and -5 in dose groups 1 and 2, and additional Flu 30 mg/m 2 /d on day -4 in … WebFeb 12, 2024 · Brief Summary: This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and …
This open-label, phase 1 trial was conducted at multiple centers in North America to evaluate the safety of afami-cel in HLA … See more Patients who were HLA-A*02:05+ in either allele, those with HLA-A*02:07 as the sole HLA-A*02 allele and those with any A*02 null allele (designated with an ‘N’; for example, A*02:32N) … See more Patients must have voluntarily agreed to participate by giving written informed consent in accordance with International Council on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and applicable local … See more The sample size for this study was not pre-specified. This phase 1 study was not statistically powered to evaluate either safety or efficacy; hence, the data were summarized descriptively. No formal hypothesis testing … See more WebApr 16, 2024 · The MAGE-A4 poster presented the discovery process and extensive preclinical validation work performed by Adaptimmune to characterize the specificity, affinity, and potency of MAGE-A4 SPEAR T-cells. The T-cell receptor (TCR) engineered to target MAGE-A4 was found to be specific for MAGE-A4 with an appropriate affinity and …
WebMay 29, 2024 · The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including #102synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by …
WebMay 29, 2024 · The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in … pronom indirect frenchWebNov 19, 2024 · IMC-C103C is designed to target tumors that express the protein Melanoma-Associated Antigen A4 (MAGE-A4), a known cancer-associated antigen expressed in a wide range of malignancies. IMC-C103C ... pronom mot flecheWebMay 6, 2024 · MAGE-A4, in particular, increases DNA damage tolerance and chemoresistance in a variety of cancers by stabilizing the E3-ligase RAD18 and promoting trans-lesion synthesis (TLS). Inhibition of the MAGE-A4:RAD18 axis could sensitize cancer cells to chemotherapeutics like platinating agents. pronom interrogatif anglais facileWebMar 24, 2024 · At one end, it contains a soluble TCR with high specificity for a differentiation antigen called glycoprotein 100 (gp100) that is highly expressed by melanoma cells; at the other is a CD3-directed... labymod chat offlineWebMAGE genes are one of the well-characterized members of the CT antigen family that includes six subfamilies, MAGE-A, MAGE-B, MAGE-C, MAGE-D, MAGE-E, and MAGE-F. All of their genes are located on chromosome X. Among these, MAGE-A, MAGE-B, and MAGE-C show expression patterns as CT antigens (11-13). Tumor expression of MAGE-A4 was pronom latin is ea idWebMar 29, 2024 · Because of the significant correlation of MAGEA4 and indices of poor prognosis, the role of this CTA may be confirmed in Esophageal squamous cell carcinoma (ESCC) aggressiveness and metastasis. Therefore, MAGEA4 may be a promising therapeutic candidate for suppressing ESCC aggressiveness pronom interrogatif anglais exerciceWebSep 1, 2024 · The commercialized T cell product ADP-A2 M4 targets MAGE-A4 antigen (Adaptimmune Corp.) and has shown significant effects in phase I trials in patients with … pronom interrogatif french